期刊论文详细信息
JOURNAL OF HEPATOLOGY 卷:56
Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib
Article
Lachenmayer, Anja1,2  Toffanin, Sara1,3  Cabellos, Laia1  Alsinet, Clara1,4,5  Hoshida, Yujin6  Villanueva, Augusto4,5  Minguez, Beatriz1  Tsai, Hung-Wen1  Ward, Stephen C.1  Thung, Swan1  Friedman, Scott L.1  Llovet, Josep M.1,4,5,7 
[1] Mt Sinai Sch Med, Div Liver Dis, Mt Sinai Liver Canc Program, Div Liver Dis,Dept Med,Tisch Canc Inst,Dept Patho, New York, NY 10029 USA
[2] Univ Hosp Dusseldorf, Dept Gen Visceral & Pediat Surg, Dusseldorf, Germany
[3] Natl Canc Inst, Dept Surg & Expt Oncol, Hepatooncol Grp, I-20133 Milan, Italy
[4] Univ Barcelona, CIBERehd, IDIBAPS, Barcelona Clin Liver Canc Grp BCLC,Translat Res L, Catalonia, Spain
[5] Univ Barcelona, CIBERehd, IDIBAPS, Liver Unit,Hosp Clin, Catalonia, Spain
[6] Broad Inst Harvard & MIT, Canc Program, Cambridge, MA USA
[7] Inst Catalana Recerca & Estudis Avancats, Barcelona, Catalonia, Spain
关键词: Hepatocellular carcinoma;    Liver cancer;    Histone modification;    Signaling pathways;    Molecular therapies;   
DOI  :  10.1016/j.jhep.2012.01.009
来源: Elsevier
PDF
【 摘 要 】

Background & Aims: Hepatocellular carcinoma (HCC) is a heterogeneous cancer in which sorafenib is the only approved systemic therapy. Histone deacetylases (HDAC) are commonly dysregulated in cancer and therefore represent promising targets for therapies, however their role in HCC pathogenesis is still unknown. We analyzed the expression of 11 HDACs in human HCCs and assessed the efficacy of the pan-HDAC inhibitor panobinostat alone and in combination with sorafenib in preclinical models of liver cancer. Methods: Gene expression and copy number changes were analyzed in a cohort of 334 human HCCs, while the effects of panobinostat and sorafenib were evaluated in three liver cancer cell lines and a murine xenograft model. Results: Aberrant HDAC expression was identified and validated in 91 and 243 HCCs, respectively. Upregulation of HDAC3 and HDAC5 mRNAs was significantly correlated with DNA copy number gains. Inhibiting HDACs with panobinostat led to strong anti-tumoral effects in vitro and vivo, enhanced by the addition of sorafenib. Cell viability and proliferation declined, while apoptosis and autophagy increased. Panobinostat increased histone H3 and HSP90 acetylation, downregulated BIRC5 (survivin) and upregulated CDH1. Combination therapy with panobinostat and sorafenib significantly decreased vessel density, and most significantly decreased tumor volume and increased survival in HCC xenografts. Conclusions: Aberrant expression of several HDACs and copy number gains of HDAC3 and HDAC5 occur in HCC. Treatment with panobinostat combined with sorafenib demonstrated the highest preclinical efficacy in HCC models, providing the rationale for clinical studies with this novel combination. (C) 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

【 授权许可】

Free   

【 预 览 】
附件列表
Files Size Format View
10_1016_j_jhep_2012_01_009.pdf 1140KB PDF download
  文献评价指标  
  下载次数:14次 浏览次数:0次